As of October 30, 2026, a Phase 4 clinical trial involving leuprolide has been updated to active, not recruiting status. The trial, registered as NCT06627530 and titled "COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer," is listed on ClinicalTrials.gov.
The study is designated Phase 4, indicating it involves an approved compound being studied further in a post-marketing context. Its current status of active, not recruiting means the trial is ongoing but is no longer enrolling new participants.
No results have been posted for this trial as part of this update. The event data confirms only the trial's title, phase, and current enrollment status as of the date listed. No efficacy or safety outcomes are included in this record.
Leuprolide is an approved compound, and this trial update reflects administrative progress in its Phase 4 study rather than new clinical findings. Readers interested in tracking this trial further can consult the ClinicalTrials.gov registry for additional procedural details as they become available.
For more background on this compound, see the leuprolide overview.